Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Authors

Institutions

Publication Details

Journal
Diabetes Care
Published
2025-12-08
DOI
https://doi.org/10.2337/dc25-2540
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Sanjiv J. Shah, Brian Lee Claggett, Pardeep S. Jhund, John W. Ostrominski et al.
Diabetes Care
Heart Failure Treatment and Management
article

Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure With Mildly Reduced or Preserved Ejection Fraction

Sanjiv J. Shah, Brian Lee Claggett, Pardeep S. Jhund, John W. Ostrominski, John J.V. McMurray, Alasdair Henderson, Katja Rohwedder, Patrick Schloemer, Meike Brinker, Michele Senni, Muthiah Vaduganathan, Carolyn S.P. Lam, Henri Lu, Bertram Pitt, Adriaan A. Voors, Scott D Solomon, Akshay S. Desai, Faïez Zannad
article en

Abstract

No abstract available for this paper.
Diabetes CareVol. 49(2)
Northwestern University (US), Brigham and Women's Hospital (US), University Medical Center Groningen (NL), Inserm (FR), University of Michigan (US), British Heart Foundation (GB), Ospedale Papa Giovanni XXIII (IT), National University Heart Centre Singapore (SG), Michigan Medicine (US), National Heart Centre Singapore (SG), Bayer (Germany) (DE), Université de Lorraine (FR), University of Lausanne (CH)
American Heart Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, Sanofi, Brigham and Women's Hospital, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Analog Devices, Edwards Lifesciences, Medpace, Boston Scientific Corporation, Regeneron Pharmaceuticals, Ionis Pharmaceuticals, Acceleron, Cytokinetics, Sarepta Therapeutics, Prothena, Fresenius Medical Care North America, MyoKardia, Verily Life Sciences, Impulse Dynamics, Moderna, British Heart Foundation, University of Glasgow, Daiichi-Sankyo, Novo Nordisk, Idorsia Pharmaceuticals, Intas Pharmaceuticals, Esperion Therapeutics, National Institutes of Health, Sanofi Pasteur, American Regent, Respicardia, Medical Research Council, National Medical Research Council, Relypsa, National Heart, Lung, and Blood Institute
Openalex Percentile: Top 44%
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.